Polysaccharide Patents (Class 514/54)
  • Patent number: 10639611
    Abstract: Compositions are disclosed herein comprising poly alpha-1,3-glucan or poly alpha-1,3-1,6-glucan polymer having an open-cell pore structure with an average pore size of about 100 nm to about 3000 nm in diameter. Such polymers have enhanced aqueous liquid absorption capacity, and can be comprised in various products having aqueous liquid absorption function. Methods of preparing glucan polymers of the compositions provided herein are also disclosed.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: May 5, 2020
    Assignee: DUPONT INDUSTRIAL BIOSCIENCES USA, LLC
    Inventors: Natnael Behabtu, Rakesh Nambiar
  • Patent number: 10639323
    Abstract: Compositions and methods are for combating inflammatory disease and particularly for use in feed or food compositions for preventing, reducing and/or treating inflammatory disorders, diseases, or discomforts. The compositions include at least one specific pectin.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 5, 2020
    Assignee: Nutrition Sciences N.V.
    Inventors: Geert Bruggeman, Erik Bruininx, Marco Van Den Berg, Paulus De Vos, Neha Mohan Sahasrabudhe, Antonius Scheurink, Hendrik Arie Schols, Jan Scholte, Lingmin Tian
  • Patent number: 10633683
    Abstract: Compositions are disclosed herein comprising at least one dextran ether compound that comprises uncharged, anionic, and/or cationic organic groups. The degree of substitution of one or more dextran ether compounds is about 0.0025 to about 3.0. Dextran from which the disclosed ether compounds can be derived can have a weight-average molecular weight of about 50-200 million Daltons and/or a z-average radius of gyration of about 200-280 nm. Also disclosed are methods of producing dextran ether compounds, as well as methods of using these ether compounds in various applications.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: April 28, 2020
    Assignee: DUPONT INDUSTRIAL BIOSCIENCES USA, LLC
    Inventors: Jayme L. Paullin, Rakesh Nambiar
  • Patent number: 10632144
    Abstract: Disclosed is a low molecular weight (1000-5000 daltons) chondroitin sulfate (CS) produced by chemical sulfation of a non-sulfated chondroitin backbone (K4 capsular polysaccharide) obtained with biotechnology techniques. The CS described is substantially monosulfated, mainly at the 6-position, with very little sulfation at the 4-position, and with a mono/disulfated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin sulfate (CS) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: April 28, 2020
    Assignee: Gnosis S.p.A.
    Inventors: Paola Bazza, Davide Bianchi, Niccolo Miraglia, Marco Valetti, Ermanno Valoti, Nicola Angelo Maria Volpi
  • Patent number: 10632141
    Abstract: The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: April 28, 2020
    Assignee: ISOThrive Inc.
    Inventors: Lee Madsen, II, Jack Oswald
  • Patent number: 10611854
    Abstract: A method for producing membrane polysaccharides from an organism selected from micro-organisms, unicellular organisms and filamentous fungi, the method including at least one step of extracting the membrane polysaccharides as well as a smaller-scale extraction of the soluble proteins, by mechanical treatment of the organism in a ball mill or by physical treatment of the organism by means of ultrasounds.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: April 7, 2020
    Assignees: ALGOSOURCE, UNIVERSITE DE NANTES
    Inventors: Jérémy Pruvost, Pascal Jaouen, Luc Marchal, Sébastien Jubeau, Joël Fleurence
  • Patent number: 10611880
    Abstract: Methods and hydrogels for preventing or reducing cellular adhesion and protein adsorption to a tissue (e.g. cardiac tissue) are disclosed. The hydrogels generally include at least two component polymers, a first polymer including an aminooxy group and a second polymer including a reactive oxo group, that are cross-linked by oxime bonds. The hydrogels are suitable for binding to and coating a tissue or cell. The hydrogels operate to reduce cellular adhesions and protein adsorption to the tissue or cell.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: April 7, 2020
    Assignee: The Regents of the University of California
    Inventors: Karen Christman, Gregory Grover, Michael Madani, Masaki Fujita
  • Patent number: 10605957
    Abstract: A gas permeable ophthalmic lens material comprises a tetraethoxysilane and an ionic silane. The ionic silane comprises positive charges and negative charges. The lens made therefrom thus comprises positive and negative charges, thus the gas permeable ophthalmic lens is hydrophilic, and prevents adhesion of bacteria in allowing the surface of the human eye to breath. A gas permeable ophthalmic lens made of the gas permeable ophthalmic lens material is also provided.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: March 31, 2020
    Assignee: ScienBiziP Consulting(Shenzhen)Co., Ltd.
    Inventor: Hsiu-Wen Chien
  • Patent number: 10596127
    Abstract: A method for manufacturing a pharmaceutical composition for reducing the frequency of urination is disclosed. The pharmaceutical composition comprises (1) an analgesic agent and (2) an ?-blocker, a 5?-reductase inhibitor or both.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 24, 2020
    Assignee: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Patent number: 10588922
    Abstract: The present invention relates to: a novel method for preparing an injectable cross-linked hydrogel containing hyaluronic acid, or one of the salts thereof, a hydrogel obtained according to said preparation method, and use of the hydrogel obtained according to said preparation method in the fields of aesthetics and medicine.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: March 17, 2020
    Assignee: KYLANE LABORATOIRES SA
    Inventor: Benedicte Vincente Tauzin
  • Patent number: 10588977
    Abstract: The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: March 17, 2020
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Uday Doshi, Kenneth T. Holeva
  • Patent number: 10583152
    Abstract: The present invention relates to a sterile aqueous ophthalmic solution comprising N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer, for use in the treatment of corneal wounds.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: March 10, 2020
    Assignee: CROMA-PHARMA GESELLSCHAFT M.B.H.
    Inventor: Martin Prinz
  • Patent number: 10555970
    Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 11, 2020
    Assignee: DARK CANYON LABORATORIES, LLC
    Inventor: Dale R. Bachwich
  • Patent number: 10555966
    Abstract: Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: February 11, 2020
    Assignee: ECONUGENICS, INC.
    Inventor: Isaac Eliaz
  • Patent number: 10548844
    Abstract: Methods of encapsulating microorganisms, or components thereof, for targeted enteric delivery to an animal host have been developed. In particular, the encapsulation provides a prolonged survival, extended retention and a pH-sensitive release of the encapsulated microorganisms or antigenic components thereof at targeted sites within the gastrointestinal tract. The formulations are useful for diagnostic, therapeutic and prophylactic purposes and can alter a host's microbial composition associated with a condition or a disease state.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: February 4, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Aaron C. Anselmo, Robert S. Langer, Ana Jaklenec
  • Patent number: 10494452
    Abstract: A low-molecular-weight fucosylated glycosaminoglycan (aTFG) containing 2,5-anhydrated talose, alditol, glycosylamine or N-substituted glycosylamine monosaccharide composition thereof, preparation method thereof, pharmaceutical compositions containing the aTFG, and use thereof for preventing and/or treating thrombotic diseases are provided. The aTFG has potent anticoagulant activity targeting at intrinsic coagulation factor Xase, and inhibiting thrombogenesis, and therefore can be used as drugs for preventing and/or treating cardiovascular and cerebrovascular diseases.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 3, 2019
    Assignee: Jiuzhitang Co., Ltd.
    Inventors: Jinhua Zhao, Mingyi Wu, Na Gao, Zi Li, Sensen Lai, Longyan Zhao
  • Patent number: 10485550
    Abstract: The present disclosure provides an elastomeric material for the delivery of an ophthalmic agent to the eye of a subject and methods of using such material.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 26, 2019
    Assignee: DUKE UNIVERSITY
    Inventors: David L. Epstein, Stuart McKinnon, Molly Walsh
  • Patent number: 10479842
    Abstract: A troche comprising at least 5 mg hyaluronan, wherein the troche is adherent, and wherein hyaluronan is released from the troche, is used to treat mucositis, including stomatitis, vestibulitis, aphthous ulcerations, lichen planus and Behcet's syndrome. A method for treating or preventing mucositis in a patient is provided, comprising applying to a mucosal surface or a tooth or orthodontic brace of a patient in need thereof an adhering troche comprising at least 5 mg hyaluronan.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: November 19, 2019
    Assignee: Quest Products, LLC
    Inventor: Jeffrey Haley
  • Patent number: 10471151
    Abstract: The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (HA) or HA mixture, whereas the HA or the HA mixture as a delivery vehicle can be a formulation including at least two HAs having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), Crohn's Disease, irritable bowel syndrome (IBS), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: November 12, 2019
    Assignee: AIHOL CORPORATION
    Inventors: Shyh-Shyan Lin, Tsung Chung Wu
  • Patent number: 10471090
    Abstract: The invention proposes a polymer solution for visco-supplementation. The polymer solution contains at least one at least partially water-soluble polysaccharide or polysaccharide derivative, one water-soluble alkali salt or alkaline earth salt of polystyrene sulfonic acid, and water, whereby the polymer solution is clear to the eye. Moreover, the invention describes a method for sterilization of the polymer solution. This method is characterized in that a mixture of at least one at least partially water-soluble polysaccharide or polysaccharide derivative, one water-soluble alkali salt or alkaline earth salt of polystyrene sulfonic acid, and water is mixed with at least 0.5 wt. % ß-propiolactone, and in that the polymer solution is stored at room temperature for at least 24 hours.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: November 12, 2019
    Assignee: HERAEUS MEDICAL GMBH
    Inventors: Sebastian Vogt, Thomas Kluge
  • Patent number: 10465015
    Abstract: A method of extracting lentinan from lentinan containing mushrooms comprising the step of contacting the mushrooms with an ionic liquid so as to obtain a lentinan rich ionic liquid solution.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: November 5, 2019
    Assignee: K Hughes & Co., Ltd.
    Inventors: Martyn Earle, Manuela Gilea
  • Patent number: 10449225
    Abstract: Provided are compositions useful as dietary supplements for the relief of unstable gastrointestinal symptoms such as constipation and diarrhea and methods of using same. The compositions consist essentially of the extract of the fruits of Coffea arabica, in combination with other materials recognized by those skilled in the art as being useful secondary ingredients in a composition for oral administration. The secondary ingredients do not affect the basic properties conferred by the presence of the extract of Coffea arabica, The extract of Coffea arabica is present in compositions according to the disclosure in relatively high amounts, and the compositions are devoid of any dietary fiber other than that incidental in the extracts, and are free from any added alginic acids or their salts. Methods according to the disclosure are described, which involve daily oral administration of the compositions described prior to mealtime.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: October 22, 2019
    Inventor: Donald L. Walters
  • Patent number: 10441677
    Abstract: Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: October 15, 2019
    Assignee: Anika Therapeutics, Inc.
    Inventors: Colin D. White, Edward S. Ahn, Sekoni Daouda Noel
  • Patent number: 10428101
    Abstract: The present invention provides a method of preparing an isolated oligosaccharide or glycolipid by preparing the oligosaccharide or glycolipid having a hydrophobic group, such as a perfluorinated alkyl or a fatty acid, and separating the oligosaccharide or glycolipid using a solid-phase extraction cartridge.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: October 1, 2019
    Assignee: The Regents of the University of California
    Inventors: Xi Chen, Hai Yu, Joel Hwang
  • Patent number: 10420793
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 24, 2019
    Assignee: Galectin Therapeutics, Inc.
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Patent number: 10420796
    Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: September 24, 2019
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Sho Funayama, Risa Nodera, Takahiro Hatanaka
  • Patent number: 10407514
    Abstract: A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: September 10, 2019
    Assignee: TX MEDIC AB
    Inventors: Lars Bruce, Ulf Brasen
  • Patent number: 10406175
    Abstract: There is provided a polymer-flavonoid conjugate, or a pharmaceutically acceptable salt thereof, uses thereof, and methods of making thereof. The disclosed polymer-flavonoid conjugates may be useful in the therapeutic and/or prophylactic treatment of a joint condition in a subject.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: September 10, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Motoichi Kurisawa, Fan Lee
  • Patent number: 10398778
    Abstract: Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: September 3, 2019
    Assignees: Galectin Therapeutics, Inc., Providence Health & Services—Oregon
    Inventors: Peter G. Traber, William L. Redmond, Eliezer Zomer, Anatole Klyosov, Stefanie N. Linch
  • Patent number: 10384072
    Abstract: There is provided a wound healing composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: August 20, 2019
    Assignee: KLOX TECHNOLOGIES INC.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Patent number: 10378953
    Abstract: A computer executable method that can be stored in a memory, the method including: visually presenting on a display of a user device a history of UV dose that was calculated based on information sensed by a UV sensor in a wearable UV sensing device; visually presenting a percentile indicator on the display, the percentile indicator being indicative of a calculated percentile of the history of UV dose; and visually presenting on the display a user-adjustable UV dose threshold interface that is adapted to allow the user to interact with the user-adjustable UV dose interface and choose a user-chosen UV dose threshold quantity.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 13, 2019
    Assignee: YouV Labs, Inc.
    Inventors: Emmanuel Dumont, Shayak Banerjee
  • Patent number: 10376577
    Abstract: Disclosed herein is a refined product obtained from a rice hull, which consists essentially of a type II arabinogalactan having a number average molecular weight in the range of 56 to 103 kDa. Also disclosed are a process for producing the refined product and use of the refined product for enhancing the biological activity of innate immune cells, as well as for treating allergy and cancer.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: August 13, 2019
    Assignee: China Medical University
    Inventors: Wen-Chuan Lin, Li-Chan Yang, Chang-Chi Hsieh
  • Patent number: 10322179
    Abstract: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: June 18, 2019
    Assignee: KLOX TECHNOLOGIES INC.
    Inventors: Remigio Piergallini, Nikolaos Loupis
  • Patent number: 10314799
    Abstract: The present invention provides use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus, for example, porcine epidemic diarrhea, porcine transmissible gastroenteritis, rotavirus diarrhea and the like.
    Type: Grant
    Filed: January 17, 2015
    Date of Patent: June 11, 2019
    Assignees: GENIFARM Laboratories Inc, GUANG ZHOU YUAN TU BIOLOGICAL AND CHEMICAL TECHNOLOGY CO. LTD
    Inventors: Yongdong Wang, Jiyuan Cao, Shifa Zhu, Wen Cheng, Zhipeng Huang
  • Patent number: 10314950
    Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: June 11, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Sarah Mayes, Christine E. Schmidt
  • Patent number: 10307496
    Abstract: Sterilization method according to which an aqueous polysaccharide solution is stored in the presence of a lactone and a buffer system for a period of at least 24 hours, and a sterile polysaccharide solution produced in this way.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: June 4, 2019
    Assignee: HERAEUS MEDICAL GMBH
    Inventors: Sebastian Vogt, Thomas Kluge
  • Patent number: 10307512
    Abstract: The present invention relates to a process for preparing a crosslinked gel of at least one polysaccharide or a salt thereof, comprising at least the steps consisting in: a) providing a solution formed from an aqueous medium comprising at least said polysaccharide(s) or a salt thereof in a non-crosslinked form, at least one difunctional or multifunctional epoxide crosslinking agent chosen from butanediol diglycidyl ether, diepoxyoctane, 1,2-bis(2,3-epoxypropyl)-2,3-ethylene, and mixtures thereof, and at least one phosphate salt; b) crosslinking the solution from step a) and, where appropriate; c) recovering said crosslinked gel formed.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 4, 2019
    Assignee: TEOXANE
    Inventors: Francois Bourdon, Stephane Meunier
  • Patent number: 10300168
    Abstract: The present invention relates to polysaccharide soft tissue fillers comprising heparosan and processes for their preparation. The polysaccharide soft tissue fillers of the present invention are advantageously used in therapeutic or cosmetic applications such as for the filling of wrinkles.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: May 28, 2019
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Alexander Linko, Andreas Krause, Franck Villain
  • Patent number: 10294295
    Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: May 21, 2019
    Assignees: INIS Biotech LLC, Consejo Nacional de Investigaciones Cientificas Y Tecnicas, Fundacion Sales
    Inventors: Gabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino
  • Patent number: 10292944
    Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 21, 2019
    Assignee: Purina Animal Nutrition LLC
    Inventors: Bill L. Miller, Jill A. Davidson, Cindie M. Luhman
  • Patent number: 10266511
    Abstract: The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound o Formula (I); and methods useful for healing wounds, preventing and treating cancer and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (1).
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: April 23, 2019
    Assignee: EUCLISES PHARMACEUTICALS, INC.
    Inventors: John J. Talley, Eduardo J. Martinez
  • Patent number: 10245280
    Abstract: Use of hyaluronic acid as the sole active ingredient for preparing compositions in particular for topical use for treating oral cavity aphthas.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: April 2, 2019
    Assignee: Bioplax Limited
    Inventor: Franco Macchi
  • Patent number: 10232007
    Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: March 19, 2019
    Assignee: WORLD FORCE TECHNOLOGIES, LLC
    Inventors: Thomas W. Konowalchuk, Jack Konowalchuk
  • Patent number: 10231990
    Abstract: The present invention relates to a sterile and/or decontaminated composition for topical use, including hyaluronic acid at a concentration of greater than or equal to 0.1 wt % relative to the total weight of the composition, at least one skin wound healing agent, optionally at least one plant extract, and at least one solvent. The invention also relates to a unit including such a composition, to a method for preparing such a composition, and to the uses thereof.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: March 19, 2019
    Assignee: Horus Pharma
    Inventors: Claude Claret, Martine Claret, Carole Gard
  • Patent number: 10220113
    Abstract: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: March 5, 2019
    Assignee: Allergan Industrie, SAS
    Inventors: Cecile Gousse, Pierre F. Lebreton, Nicolas Prost
  • Patent number: 10206944
    Abstract: Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and anti-microbial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: February 19, 2019
    Assignee: ALTERGON S.A.
    Inventors: Mario De Rosa, Chiara Schiraldi
  • Patent number: 10206895
    Abstract: The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: February 19, 2019
    Assignee: ARBOR PHARMACEUTICALS, INC.
    Inventors: H. Greg Thomas, Jeffrey S. Kiel
  • Patent number: 10201561
    Abstract: An object of the present invention is to provide an antiviral fiber assembly in which an antiviral agent is retained with chemical stability over a long period of time, and which is gentle to the human body. A further object of the present invention is to provide a fiber assembly with cellulose sulfate that can exhibit sufficient antiviral activity over a long period of time. Further, another object of the present invention is to provide a textile product obtained using such a fiber assembly. The present invention provides a fiber assembly with cellulose sulfate, wherein the hyaluronidase inhibitory activity is 50% or higher; and a process for producing a fiber assembly with cellulose sulfate, including treating a fiber assembly with an aqueous cellulose sulfate solution and drying, then treating the same with a pH buffer solution and drying.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: February 12, 2019
    Assignees: ES FiberVisions CO., LTD., ES FiberVisions Hong Kong Limited, ES FiberVisions LP, ES FiberVisions ApS
    Inventors: Yoshiko Watanabe, Kazuyuki Sakamoto
  • Patent number: 10195312
    Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: February 5, 2019
    Inventor: Xin Ji
  • Patent number: 10195239
    Abstract: Disclosed herein is an extract obtainable from Trigonella foenum-graecum. In particular, the extract is obtainable by a process comprising the steps of preparing a mixture of a plant material obtained from Trigonella foenum-graecum and liquid, incubating said mixture for at least 3 hours, heating of said mixture, and recovering a liquid extract from mixture. The extract is useful in the manufacture of various types of compositions, such as pharmaceutical compositions, disinfectant or preservation agents. The pharmaceutical may be used for the treatment or prevention of an inflammatory disease or an infectious condition.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: February 5, 2019
    Assignee: V-BIOTEK HOLDING APS
    Inventor: Jens Steen Olsen